The National Cancer Institute's (NCI's) human tumor cell line panel for screening potential new anticancer drugs is now operational (/). Its implementation and the demonstration of its feasibility represent a technical and organizational tour de force. The rationale for the change in the primary screen from leukemias in mice to the array of 60 human cancer cell lines was earlier debated in contrasting editorials in this journal (2,3).
The new screening panel occupies a central position in the NCI's continued commitment to anticancer drug development ( Fig. 1) . A major implicit assumption in this schema is the presence of novel, highly active agents among the thousands funnelled into the system. The acquisition of candidate compounds is therefore the initial limiting factor. How did our current complement of 40 or so active anticancer drugs arrive at the first stage of development, and where can we expect future agents to originate?
Sources of New Agents Table 1 lists the pathways to discovery of those anticancer drugs that are commercially available or in the late stages of clinical trials. Approximately half of these drugs were discovered by systematic screening of chemicals and natural products (plant extracts and microbial fermentation broths). An emphasis by the NCI on new natural products from unexplored marine and tropical sources has a compelling precedent in our armamentarium. The diverse and complex structures and mechanisms of natural products in pharmacology are likely to continue to transcend the imagination of human chemists.
Analogues of known active compounds have yielded new agents with advantageous pharmaceutical properties, antitumor spectrum, and lower toxicity. Commercial sources that generate most drug analogues may find that the NCI's screening panel complements their traditional evaluation of these compounds. Particularly intriguing in characterizing analogues will be the COMPARE computer program, which develops a "fingerprint" or profile of activity of new agents in the panel of cell lines and analyzes their similarity to known drugs (4). There are historical precedents for substantially novel properties of analogues, e.g., the shift in cytotoxic target from tubulins to topoisomerase II produced by the semisynthesis of etoposide from podophyllotoxin.
Perhaps the most important source of candidates for future screening will be ongoing basic research and the rational pursuit of serendipitous observations. The discoveries of antifolates and platinum agents are marvelous examples of such intellectual curiosity, vision, and persistence at work. In both cases, the therapeutic application was unanticipated when the initial experiment was performed. Sidney Farber observed that folates stimulated the growth of leukemias in his patients and engaged synthetic chemists in a quest for the first antimetabolites (5). Barnett Rosenberg isolated cisplatin by following up an anomalous observation while studying the effects of electric fields on bacterial growth (6). Vigorous support of fundamental, investigator-initiated research will surely yield new therapeutic directions that have not yet been imagined.
The antimetabolites and hormonal agents are the major classes of anticancer drugs that evolved from rational applications of advances in biochemistry and tumor biology. NCI's funding of drug discovery groups seeks to extend this paradigm to areas of current therapeutic promise. The cell line panel may have a role in the further selection of compounds that are first screened by biochemical assays of defined molecular targets, such as the tyrosine kinases and growth factor receptors.
Histospecificity
One of the premises supporting the screening panel has been the possibility of discovering agents that are relatively specific for a certain tumor type. There are various precedents for such "histospecificity." Mitotane's use in adrenocortical carcinomas arose from its observed toxicity to the adrenal cortex. Streptozocin is relatively toxic to both normal and neoplastic pancreatic islet cells. The activity of asparaginase is relatively specific for acute lymphoblastic leukemias. The use of ]MIBG (meta-iodo-benzylguanidine) as a radiopharmaceutical exploits the tissue-specific uptake of this agent by neuroendocrine tissues and tumors (7, 8) .
The agent that prompted particular interest in the detection of histospecificity by the cell line panel is ipomeanol (9). This fungal product, a potent lung toxin, is activated by an isoform of cytochrome P 450 in the Clara cells of mammalian bronchi. Ipomeanol is currently in phase I clinical trials. Preliminary studies indicate that a small fraction of human lung cancers expresses the specific activating enzyme for this agent, and the current subpanel of human lung cancer cell lines does not identify it as particularly active.
The examples cited were developed from empirical observations rather than from screening of unknown compounds. Additional opportunities for the development of histospecific anticancer drugs include patterns of oncogene and tumor suppressor gene expression characteristic for certain cancers and the demonstration of linkages between differentiation and oncogenesis at sites of chromosomal translocations.
The ability of the screening panel to detect histospecificity will depend on the degree to which the subpanels are indeed representative of certain tumor types. Moreover, there are likely to be many other factors, such as the multidrug resistance gene, contributing to the drug responsiveness of putative histospecific agents. Such factors may be prospectively identified in models of resistance or by characteristic response patterns in the COM-PARE program. The expression of mdrl gene is currently being investigated for the entire panel (Grever M: personal communication). Similar efforts should be continued for all the known factors that confer drug resistance or tissue specificity among these lines.
Secondary Screen A primary screen should appropriately be over-predictive rather than overly selective. The criteria for choosing candidates from this screen will be subjective, arbitrary, and empirical, but many candidates will emerge. The nature and function of the secondary in vivo screens are themselves challenging problems and vital to the success of the drug discovery enterprise. Three quarters of the human cell lines in the panel also form tumors in athymic mice, thus offering an opportunity to evaluate a therapeutic ratio in tumors formed from the most sensitive lines in the panel. However, advances in clinical practice (growth factors, stem cell transfusions, and other supportive measures) have expanded the therapeutic horizon by a two-fold to 10-fold increase in dose intensity. These changes pose a major issue for the development of new agents. Myelosuppression is less and less of a factor in humans, but it remains the most prominent dose-limiting toxicity in animal models. Will important agents be rejected because of toxic effects in animals that are not relevant in humans? One potential solution (for agents involved in multidrug resistance) is the use of a transgenic mouse that expresses the human mdrl gene at high levels in bone marrow (10).
Validation
Some insight into the capabilities of the cell line screen might be obtained retrospectively by analyzing its performance in relation to the agents in Table 1 . How does the screen perform in detecting these drugs? It is obvious that any agent that requires metabolic activation in the liver or by other extratumoral tissues will be inert in the current screen. Thus, cyclophosphamide and ifosfamide are inactive. This disadvantage compared with the primary in vivo murine leukemia models might be overcome by incorporating into the panel cellular models that express various mixed-function oxidases, e.g., hepatoma lines or transfected cells.
In addition to those agents that require metabolic activation, other classes of drugs might be missed by the screen: those that are targeted to intracellular and stromal interactions in tumor tissues (e.g., angiogenesis, invasion, and metastasis) and those that act at least in part via effector cells (e.g., interferons).
An evaluation of the impact of the new screening panel on the discovery of new anticancer agents is years away. Meanwhile, many critical issues will require ongoing attention: maximizing the acquisition of new compounds into the system, factoring bioactivation into the primary screen, the selection criteria for secondary screening, and the nature of the secondary screen. Incorporation of a panel of biochemical assays for selected molecular targets, such as growth factor receptors, should be considered as a complement to the cytotoxicity end points used in the cell lines.
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Beyond its important role in the flow of potential new drugs to the clinic, the panel is likely to contribute to many other aspects of cancer biology. The genetic and biochemical properties of these cell lines should be further investigated. As the mechanisms of drug action and cellular and molecular determinants of drug sensitivity are increasingly understood, the program's database may yield hitherto unsuspected insights into new agents at their earliest stages of development. This experiment in drug discovery may also become our most comprehensive laboratory model of human cancers. press the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci U S A 88: [547] [548] [549] [550] [551] 1991 Reversal of Misfortune: TIMP-2 Inhibits Tumor Cell Invasion Jacqueline E. Testa* James P. Quigley
Under normal physiological conditions in vivo, proteolytic enzymes are strictly regulated in their synthesis, secretion, and catalytic activity. The relative abundance of natural protease inhibitors in body tissues and blood plasma serves as a potent negative regulatory mechanism for controlling unrestricted proteolysis. If the molar balance between proteases and their inhibitors shifts in favor of the enzyme, proteolytic degradation occurs. This can be beneficial, as in the case of wound healing or fibrin clot lysis, or it can be disastrous, as in the case of tumor invasion and metastasis. Elevated expression of certain serine and cysteine proteases and metalloproteases has been implicated in malignant tumor cell behavior, apparently due to an imbalance between enzyme and inhibitor favoring excessive proteolysis, resulting in invasion and metastasis (1-4) . Albini et al. (5) , in this issue of the Journal, and DeClerck et aJ. (6), in a recent issue of Cancer Research, describe the use of exogenously added purified tissue inhibitor of metalloproteinase-2 (TIMP-2) to reverse the invasive phenotype of tumor cells in vitro. TTMP-2, a recently discovered metalloprotease inhibitor (7-9), is a 21-kd, nonglycosylated protein, which preferentially forms a 1:1 complex with the zymogen form of 72-kd type IV collagenase/gelatinase. The deduced amino acid sequence of TIMP-2 is 65% homologous to that of a previously described inhibitor, 11) . TIMP-1 is a 29-kd glycoprotein that preferentially binds to the proenzyme form of the 92-kd type IV collagenase/gelatinase (12,13). Upon activation, both the 72-and 92-kd enzymes can be inhibited by binding a second molecule of TIMP-1 or TIMP-2 (8). TIMP-1 and TIMP-2 can also inhibit all members of the other metalloprotease subclasses tested thus far (3, 14) .
Three major subclasses of the matrix metalloprotease family have been identified to date (14). The first subclass includes interstitial and polymorphonuclear cell collagenases, which degrade collagens type I, II, and III. The second subclass contains the 72-kd type IV collagenase/gelatinase, which degrades collagens type IV, V, and VII, as well as gelatin, and the 92-kd type IV collagenase/gelatinase, which degrades collagens type IV and V and gelatin. Members of the third subclass include stromelysin (transin), stromelysin-2 (transin-2), and putative metalloprotease-1 (PUMP-1). Stromelysin degrades matrix proteoglycans; laminin; fibronectin; collagens type III, IV, and V; and gelatin. Stromelysin-2 degrades the same matrix components as stromelysin, with the exception of the proteoglycans, and PUMP-1 degrades fibronectin and gelatin. Recently, a gene designated stromelysin-3 has been cloned by subtractive hybridization from an invasive breast carcinoma (75).
Albini et al. (5), using a reconstituted basement membrane (matrigel) invasion assay, report that HT-1080 tumor cell invasion decreased approximately 85% when exogenous, purified TIMP-2 was added to the system. They also showed that the natural protein inhibitor was as effective in abrogating invasion as a polyclonal antiserum directed against the 72-kd type IV collagenase/gelatinase. As HT-1080 cells secrete the 72-kd type IV collagenase/gelatinase and, to a lesser extent, the 92-kd type IV collagenase/gelatinase, these results indicated that matrigel in-
